Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options

Paul Hodgkins, Monica Shaw, David Coghill, Lily Hechtman, Paul Hodgkins, Monica Shaw, David Coghill, Lily Hechtman

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is one of the most common neurodevelopmental disorders among school-aged children. It is highly symptomatic and associated with significant impairment. This review examines the role of stimulant medications in the treatment of children and adolescents with ADHD. Published clinical studies that compared methylphenidate- and amfetamine-based stimulants in children and adolescents with ADHD support the therapeutic utility of stimulant treatments, and suggest robust efficacy and acceptable safety outcomes in groups treated with either stimulant. Evidence-based guidelines agree that each patient with ADHD is unique and individual treatment strategies that incorporate both drug and non-drug treatment options should be sought. In seeking to optimize individual response and outcomes to stimulant therapy, important considerations include the selection of stimulant class, the choice of long- or short-acting stimulant formulations, addressing effectively any emergent adverse effects and strategies aimed at enhancing adherence to dosing regimen and persistence on therapy.

Figures

Fig. 1
Fig. 1
Overlapping but distinct putative mechanisms of action of a methylphenidate (MPH) and b amfetamine (AMF) at the dopamine synapse. VMAT2 vesicular monoamine transporter 2
Fig. 2
Fig. 2
Effect sizes and confidence intervals for ADHD-RS and CGI outcomes in children. Black diamonds and horizontal black lines represent standardized mean difference effect sizes and 95 % confidence intervals, respectively. Pooled results are depicted as open diamonds with the effect size in the centre of the diamond and the 95 % confidence intervals depicted by the left and right extremities of the diamond. ADHD-RS attention-deficit/hyperactivity disorder rating scale, CGI clinical global impressions of ADHD severity, LDX lisdexamfetamine dimesylate, MAS mixed amfetamine salts, MPH methylphenidate, OROS osmotic release oral system, TS transdermal system. Figure adapted from Faraone [37], with permission

References

    1. American Academy of Pediatrics ADHD: Clinical Practice Guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011;128:1007–1022. doi: 10.1542/peds.2011-2107B.
    1. American Psychiatric Association . Diagnostic and statistical manual of mental disorders, Fourth Edition, Text Revision (DSM-IV-TR) Washington DC: American Psychiatric Association; 2000.
    1. Antshel KM, Hargrave TM, Simonescu M, Kaul P, Hendricks K, Faraone SV. Advances in understanding and treating ADHD. BMC Med. 2011;9:72. doi: 10.1186/1741-7015-9-72.
    1. Arnold EL. Methylphenidate vs. amphetamine: comparative review. J Atten Disord. 2000;3:200–211. doi: 10.1177/108705470000300403.
    1. Arnold LE, Christopher J, Huestis R, Smeltzer DJ. Methylphenidate vs dextroamphetamine vs caffeine in minimal brain dysfunction: controlled comparison by placebo washout design with Bayes’ analysis. Arch Gen Psychiatry. 1978;35:463–473. doi: 10.1001/archpsyc.1978.01770280073008.
    1. Arnsten AF (2009) The emerging neurobiology of attention deficit hyperactivity disorder: the key role of the prefrontal association cortex. J Pediatr 154:I–S43
    1. Arnsten AF. Fundamentals of attention-deficit/hyperactivity disorder: circuits and pathways. J Clin Psychiatry. 2006;67(Suppl 8):7–12.
    1. Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355:1064–1069. doi: 10.1016/S0140-6736(00)02039-0.
    1. Banaschewski T, Coghill D, Santosh P, Zuddas A, Asherson P, Buitelaar J, Danckaerts M, Dopfner M, Faraone SV, Rothenberger A, Sergeant J, Steinhausen HC, Sonuga-Barke EJ, Taylor E. Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006;15:476–495. doi: 10.1007/s00787-006-0549-0.
    1. Bellgrove MA, Barry E, Johnson KA, Cox M, Daibhis A, Daly M, Hawi Z, Lambert D, Fitzgerald M, McNicholas F, Robertson IH, Gill M, Kirley A. Spatial attentional bias as a marker of genetic risk, symptom severity, and stimulant response in ADHD. Neuropsychopharmacology. 2008;33:2536–2545. doi: 10.1038/sj.npp.1301637.
    1. Bonetti M, Gelber RD. Patterns of treatment effects in subsets of patients in clinical trials. Biostatistics. 2004;5:465–481. doi: 10.1093/biostatistics/kxh002.
    1. Borcherding BG, Keysor CS, Cooper TB, Rapoport JL. Differential effects of methylphenidate and dextroamphetamine on the motor activity level of hyperactive children. Neuropsychopharmacology. 1989;2:255–263. doi: 10.1016/0893-133X(89)90029-8.
    1. Brennan AR, Arnsten AF. Neuronal mechanisms underlying attention deficit hyperactivity disorder: the influence of arousal on prefrontal cortical function. Ann N Y Acad Sci. 2008;1129:236–245. doi: 10.1196/annals.1417.007.
    1. Brown GL, Hunt RD, Ebert MH, Bunney WE, Jr, Kopin IJ. Plasma levels of d-amphetamine in hyperactive children serial behavior and motor responses. Psychopharmacology. 1979;62:133–140. doi: 10.1007/BF00427126.
    1. Burkins JA, Ciaverelli R, Frampton KK, Henschen G, McCarthy DP, Nardozzi LJ, Saldarini C, Scherzer A, Wadle C (2010) Clinical practice guideline for patients with attention deficit/hyperactivity disorder. Magellan Health Services Inc, MA, USA. . Accessed 11 April 2012
    1. Cai T, Tian L, Wong PH, Wei LJ. Analysis of randomized comparative clinical trial data for personalized treatment selections. Biostatistics. 2011;12:270–282. doi: 10.1093/biostatistics/kxq060.
    1. Canadian Attention Deficit Disorder Resource Alliance (CADDRA) (2011) Canadian ADHD Practice (CAP) Guidelines, 3rd edn. Toronto, ON. . Accessed 11 April 2012
    1. Carlson CL, Pelham WE, Jr, Milich R, Dixon J. Single and combined effects of methylphenidate and behavior therapy on the classroom performance of children with attention-deficit hyperactivity disorder. J Abnorm Child Psychol. 1992;20:213–232. doi: 10.1007/BF00916549.
    1. Castellanos FX, Elia J, Kruesi MJ, Marsh WL, Gulotta CS, Potter WZ, Ritchie GF, Hamburger SD, Rapoport JL. Cerebrospinal fluid homovanillic acid predicts behavioral response to stimulants in 45 boys with attention deficit/hyperactivity disorder. Neuropsychopharmacology. 1996;14:125–137. doi: 10.1016/0893-133X(95)00077-Q.
    1. Christensen L, Sasane R, Hodgkins P, Harley C, Tetali S. Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population. Curr Med Res Opin. 2010;26:977–989. doi: 10.1185/03007991003673617.
    1. Cohen J. A power primer. Psychol Bull. 1992;112:155–159. doi: 10.1037/0033-2909.112.1.155.
    1. Curatolo P, D’Agati E, Moavero R. The neurobiological basis of ADHD. Ital J Pediatr. 2010;36:79. doi: 10.1186/1824-7288-36-79.
    1. Dahabreh IJ, Terasawa T, Castaldi PJ, Trikalinos TA. Systematic review: anti-epidermal growth factor receptor treatment effect modification by KRAS mutations in advanced colorectal cancer. Ann Intern Med. 2011;154:37–49.
    1. Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie: Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-K-uJ (2007) Hyperkinetische Störungen (F90). . Accessed 5 April 2012
    1. Dew RE, Kollins SH. Lisdexamfetamine dimesylate: a new option in stimulant treatment for ADHD. Expert Opin Pharmacother. 2010;11:2907–2913. doi: 10.1517/14656566.2010.531009.
    1. Diamond A. Attention-deficit disorder (attention-deficit/hyperactivity disorder without hyperactivity): a neurobiologically and behaviorally distinct disorder from attention-deficit/hyperactivity disorder (with hyperactivity) Dev Psychopathol. 2005;17:807–825. doi: 10.1017/S0954579405050388.
    1. Dopheide JA. The role of pharmacotherapy and managed care pharmacy interventions in the treatment of ADHD. Am J Manag Care. 2009;15:S141–S150.
    1. Early Breast Cancer Trialists’ Collaborative Group Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717. doi: 10.1016/S0140-6736(05)66544-0.
    1. Early Breast Cancer Trialists’ Collaborative Group Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet. 1998;351:1451–1467. doi: 10.1016/S0140-6736(97)11423-4.
    1. Easton N, Steward C, Marshall F, Fone K, Marsden C. Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. Neuropharmacology. 2007;52:405–414. doi: 10.1016/j.neuropharm.2006.07.035.
    1. Efron D, Jarman F, Barker M. Methylphenidate versus dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics. 1997;100:E6. doi: 10.1542/peds.100.6.e6.
    1. Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics. 1997;100:662–666. doi: 10.1542/peds.100.4.662.
    1. Elia J. Attention deficit/hyperactivity disorder: pharmacotherapy. Psychiatry (Edgmont) 2005;2:27–35.
    1. Elia J, Borcherding BG, Potter WZ, Mefford IN, Rapoport JL, Keysor CS. Stimulant drug treatment of hyperactivity: biochemical correlates. Clin Pharmacol Ther. 1990;48:57–66. doi: 10.1038/clpt.1990.118.
    1. Elia J, Borcherding BG, Rapoport JL, Keysor CS. Methylphenidate and dextroamphetamine treatments of hyperactivity: are there true nonresponders? Psychiatry Res. 1991;36:141–155. doi: 10.1016/0165-1781(91)90126-A.
    1. Elia J, Welsh PA, Gullotta CS, Rapoport JL. Classroom academic performance: improvement with both methylphenidate and dextroamphetamine in ADHD boys. J Child Psychol Psychiatry. 1993;34:785–804. doi: 10.1111/j.1469-7610.1993.tb01071.x.
    1. Faraone SV. Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults. J Atten Disord. 2012;16:128–137. doi: 10.1177/1087054710379738.
    1. Faraone SV. Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. P T. 2009;34:678–694.
    1. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry. 2010;19:353–364. doi: 10.1007/s00787-009-0054-3.
    1. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes. J Clin Psychiatry. 2009;71:754–763. doi: 10.4088/JCP.08m04902pur.
    1. Faraone SV, Mick E. Molecular genetics of attention deficit hyperactivity disorder. Psychiatr Clin N Am. 2010;33:159–180. doi: 10.1016/j.psc.2009.12.004.
    1. Fegert JM, Slawik L, Wermelskirchen D, Nubling M, Muhlbacher A. Assessment of parents’ preferences for the treatment of school-age children with ADHD: a discrete choice experiment. Expert Rev Pharmacoecon Outcomes Res. 2011;11:245–252. doi: 10.1586/erp.11.22.
    1. Findling RL. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review. Clin Ther. 2008;30:942–957. doi: 10.1016/j.clinthera.2008.05.006.
    1. Froehlich TE, McGough JJ, Stein MA. Progress and promise of attention-deficit hyperactivity disorder pharmacogenetics. CNS Drugs. 2010;24:99–117. doi: 10.2165/11530290-000000000-00000.
    1. Goodman DW. Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorder. P T. 2010;35:273–287.
    1. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Dopfner M, Hamilton R, Hollis C, Holtmann M, Hulpke-Wette M, Lecendreux M, Rosenthal E, Rothenberger A, Santosh P, Sergeant J, Simonoff E, Sonuga-Barke E, Wong IC, Zuddas A, Steinhausen HC, Taylor E. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry. 2011;20:17–37. doi: 10.1007/s00787-010-0140-6.
    1. Graham J, Coghill D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs. 2008;22:213–237. doi: 10.2165/00023210-200822030-00003.
    1. Heal DJ, Smith SL, Findling RL. ADHD: current and future therapeutics. Curr Top Behav Neurosci. 2012;9:361–390. doi: 10.1007/7854_2011_125.
    1. Heal DJ, Smith SL, Kulkarni RS, Rowley HL. New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD. Pharmacol Biochem Behav. 2008;90:184–197. doi: 10.1016/j.pbb.2008.03.016.
    1. Hermens DF, Cooper NJ, Kohn M, Clarke S, Gordon E. Predicting stimulant medication response in ADHD: evidence from an integrated profile of neuropsychological, psychophysiological and clinical factors. J Integr Neurosci. 2005;4:107–121. doi: 10.1142/S0219635205000653.
    1. Hungund BL, Perel JM, Hurwic MJ, Sverd J, Winsberg BG. Pharmacokinetics of methylphenidate in hyperkinetic children. Br J Clin Pharmacol. 1979;8:571–576. doi: 10.1111/j.1365-2125.1979.tb01046.x.
    1. Jones SR, Gainetdinov RR, Wightman RM, Caron MG. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci. 1998;18:1979–1986.
    1. Kahlig KM, Binda F, Khoshbouei H, Blakely RD, McMahon DG, Javitch JA, Galli A. Amphetamine induces dopamine efflux through a dopamine transporter channel. Proc Natl Acad Sci USA. 2005;102:3495–3500. doi: 10.1073/pnas.0407737102.
    1. Karapetis CS, Khambata-Ford S, Jonker DJ, O’Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–1765. doi: 10.1056/NEJMoa0804385.
    1. Kuczenski R, Segal DS. Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J Neurochem. 1997;68:2032–2037. doi: 10.1046/j.1471-4159.1997.68052032.x.
    1. Lagakos SW. The challenge of subgroup analyses–reporting without distorting. N Engl J Med. 2006;354:1667–1669. doi: 10.1056/NEJMp068070.
    1. Läkemedelsverket (2009) Läkemedelsbehandling av ADHD—Ny rekommendation. . Accessed 5 April 2012
    1. Lloyd A, Hodgkins P, Dewilde S, Sasané R, Falcner S, SB E. Methylphenidate delivery mechanisms for the treatment of children with attention deficit hyperactivity disorder: Heterogeneity in parent preferences. Int J Technol Assess Health Care. 2011;27:215–223. doi: 10.1017/S0266462311000249.
    1. Marcus SC, Wan GJ, Kemner JE, Olfson M. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 2005;159:572–578. doi: 10.1001/archpedi.159.6.572.
    1. Markowitz JS, DeVane CL, Pestreich LK, Patrick KS, Muniz R. A comprehensive in vitro screening of d-, l-, and dl-threo-methylphenidate: an exploratory study. J Child Adolesc Psychopharmacol. 2006;16:687–698. doi: 10.1089/cap.2006.16.687.
    1. May DE, Kratochvil CJ. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy. Drugs. 2010;70:15–40. doi: 10.2165/11530540-000000000-00000.
    1. McDonagh M, Peterson K, Dana T, Thakurta S (2007) Drug Class Review on Pharamcologic Treatments for ADHD. . Accessed 27 September 2011. Oregon Health and Science University, Portland, Oregon
    1. Ministerio de Sanidad PSeI (2010) Guía de Práctica Clínica sobre el trastorno por déficit de atención con hiperactividad (TDAH) en niños y adolescentes. . Accessed 5 April 2012
    1. Muhlbacher AC, Rudolph I, Lincke HJ, Nubling M. Preferences for treatment of attention-deficit/hyperactivity disorder (ADHD): a discrete choice experiment. BMC Health Serv Res. 2009;9:149. doi: 10.1186/1472-6963-9-149.
    1. National Health Service (2010) Prescription cost analysis, England–2010. . Accessed 1 June 2011
    1. National Institute for Health and Clinical Excellence (2009) Diagnosis and management of ADHD in children, young people and adults. National Clinical Practice Guideline Number 72. London, UK. . Accessed 11 April 2012
    1. Pappadopulos E, Jensen PS, Chait AR, Arnold LE, Swanson JM, Greenhill LL, Hechtman L, Chuang S, Wells KC, Pelham W, Cooper T, Elliott G, Newcorn JH. Medication adherence in the MTA: saliva methylphenidate samples versus parent report and mediating effect of concomitant behavioral treatment. J Am Acad Child Adolesc Psychiatry. 2009;48:501–510. doi: 10.1097/CHI.0b013e31819c23ed.
    1. Pelham WE, Aronoff HR, Midlam JK, Shapiro CJ, Gnagy EM, Chronis AM, Onyango AN, Forehand G, Nguyen A, Waxmonsky J. A comparison of ritalin and adderall: efficacy and time-course in children with attention-deficit/hyperactivity disorder. Pediatrics. 1999;103:e43. doi: 10.1542/peds.103.4.e43.
    1. Pelham WE, Gnagy EM, Chronis AM, Burrows-MacLean L, Fabiano GA, Onyango AN, Meichenbaum DL, Williams A, Aronoff HR, Steiner RL. A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/hyperactivity disorder. Pediatrics. 1999;104:1300–1311. doi: 10.1542/peds.104.6.1300.
    1. Pelham WE, Gnagy EM, Greiner AR, Hoza B, Hinshaw SP, Swanson JM, Simpson S, Shapiro C, Bukstein O, Baron-Myak C, McBurnett K. Behavioral versus behavioral and pharmacological treatment in ADHD children attending a summer treatment program. J Abnorm Child Psychol. 2000;28:507–525. doi: 10.1023/A:1005127030251.
    1. Pelham WE, Jr, Carlson C, Sams SE, Vallano G, Dixon MJ, Hoza B. Separate and combined effects of methylphenidate and behavior modification on boys with attention deficit-hyperactivity disorder in the classroom. J Consult Clin Psychol. 1993;61:506–515. doi: 10.1037/0022-006X.61.3.506.
    1. Pelham WE, Jr, Greenslade KE, Vodde-Hamilton M, Murphy DA, Greenstein JJ, Gnagy EM, Guthrie KJ, Hoover MD, Dahl RE. Relative efficacy of long-acting stimulants on children with attention deficit-hyperactivity disorder: a comparison of standard methylphenidate, sustained-release methylphenidate, sustained-release dextroamphetamine, and pemoline. Pediatrics. 1990;86:226–237.
    1. Pelham WE, Jr, Wheeler T, Chronis A. Empirically supported psychosocial treatments for attention deficit hyperactivity disorder. J Clin Child Psychol. 1998;27:190–205. doi: 10.1207/s15374424jccp2702_6.
    1. Peto R. Misleading subgroup analyses in GISSI. Am J Cardiol. 1990;66:771–772. doi: 10.1016/0002-9149(90)91149-Z.
    1. Pliszka S. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46:894–921. doi: 10.1097/chi.0b013e318054e724.
    1. Pliszka SR, Browne RG, Olvera RL, Wynne SK. A double-blind, placebo-controlled study of Adderall and methylphenidate in the treatment of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2000;39:619–626. doi: 10.1097/00004583-200005000-00016.
    1. Pliszka SR, Crismon ML, Hughes CW, Corners CK, Emslie GJ, Jensen PS, McCracken JT, Swanson JM, Lopez M. The Texas Children’s Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45:642–657. doi: 10.1097/01.chi.0000215326.51175.eb.
    1. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med. 2002;21:2917–2930. doi: 10.1002/sim.1296.
    1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164:942–948. doi: 10.1176/appi.ajp.164.6.942.
    1. Ramos-Quiroga JA, Bosch R, Castells X, Valero S, Nogueira M, Gomez N, Yelmo S, Ferrer M, Martinez Y, Casas M. Effect of switching drug formulations from immediate-release to extended-release OROS methylphenidate: a chart review of Spanish adults with attention-deficit hyperactivity disorder. CNS Drugs. 2008;22:603–611. doi: 10.2165/00023210-200822070-00005.
    1. Reeves G, Anthony B. Multimodal treatments versus pharmacotherapy alone in children with psychiatric disorders: implications of access, effectiveness, and contextual treatment. Paediatr Drugs. 2009;11:165–169. doi: 10.2165/00148581-200911030-00002.
    1. Robertson SD, Matthies HJ, Galli A. A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters. Mol Neurobiol. 2009;39:73–80. doi: 10.1007/s12035-009-8053-4.
    1. Sanchez RJ, Crismon ML, Barner JC, Bettinger T, Wilson JP. Assessment of adherence measures with different stimulants among children and adolescents. Pharmacotherapy. 2005;25:909–917. doi: 10.1592/phco.2005.25.7.909.
    1. Scottish Intercollegiate Guidelines Network (2009) Management of attention deficit and hyperkinetic disorders in children and young people: a national clinical guideline. . Accessed 5 April 2012
    1. Seixas M, Weiss M, Muller U. Systematic review of national and international guidelines on attention-deficit hyperactivity disorder. J Psychopharmacol. 2012;26:753–765. doi: 10.1177/0269881111412095.
    1. Sharp WS, Walter JM, Marsh WL, Ritchie GF, Hamburger SD, Castellanos FX. ADHD in girls: clinical comparability of a research sample. J Am Acad Child Adolesc Psychiatry. 1999;38:40–47. doi: 10.1097/00004583-199901000-00018.
    1. Solomon SD, Rice MM, Jablonski JA, Jose P, Domanski M, Sabatine M, Gersh BJ, Rouleau J, Pfeffer MA, Braunwald E. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with ACE inhibition (PEACE) trial. Circulation. 2006;114:26–31. doi: 10.1161/CIRCULATIONAHA.105.592733.
    1. Steele M, Jensen PS, Quinn DM. Remission versus response as the goal of therapy in ADHD: a new standard for the field? Clin Ther. 2006;28:1892–1908. doi: 10.1016/j.clinthera.2006.11.006.
    1. Stein MA, McGough JJ (2008) The pharmacogenomic era: promise for personalizing attention deficit hyperactivity disorder therapy. Child Adolesc Psychiatr Clin N Am 17:475–490, xi–xii
    1. Sulzer D, Sonders MS, Poulsen NW, Galli A. Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol. 2005;75:406–433. doi: 10.1016/j.pneurobio.2005.04.003.
    1. Taylor E, Dopfner M, Sergeant J, Asherson P, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Rothenberger A, Sonuga-Barke E, Steinhausen HC, Zuddas A. European clinical guidelines for hyperkinetic disorder–first upgrade. Eur Child Adolesc Psychiatry. 2004;13(Suppl 1):I7–I30.
    1. The MTA Cooperative Group A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal treatment study of children with ADHD. Arch Gen Psychiatry. 1999;56:1073–1086. doi: 10.1001/archpsyc.56.12.1073.
    1. The Royal Australasian College of Physicians (2009) Australian guidelines on attention deficit hyperactivity disorder (ADHD). . Accessed 01 June 2011
    1. Tian L, Cai T, Wei LJ. Identifying subjects who benefit from additional information for better prediction of the outcome variables. Biometrics. 2009;65:894–902. doi: 10.1111/j.1541-0420.2008.01125.x.
    1. Volkow ND, Fowler JS, Wang G, Ding Y, Gatley SJ. Mechanism of action of methylphenidate: insights from PET imaging studies. J Atten Disord. 2002;6(Suppl 1):S31–S43.
    1. Volkow ND, Wang GJ, Fowler JS, Gatley SJ, Logan J, Ding YS, Hitzemann R, Pappas N. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry. 1998;155:1325–1331.
    1. Wigal SB, Kollins SH, Childress AC, Squires L. A 13-hour laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3:17. doi: 10.1186/1753-2000-3-17.
    1. Wilson HK, Cox DJ, Merkel RL, Moore M, Coghill D. Effect of extended release stimulant-based medications on neuropsychological functioning among adolescents with attention-deficit/hyperactivity disorder. Arch Clin Neuropsychol. 2006;21:797–807. doi: 10.1016/j.acn.2006.06.016.
    1. Winsberg BG, Press M, Bialer I, Kupietz S. Dextroamphetamine and methylphenidate in the treatment of hyperactive-aggressive children. Pediatrics. 1974;53:236–241.
    1. Wolraich ML, Doffing MA. Pharmacokinetic considerations in the treatment of attention-deficit hyperactivity disorder with methylphenidate. CNS Drugs. 2004;18:243–250. doi: 10.2165/00023210-200418040-00004.
    1. World Health Organization Collaborating Centre for Drug Statistics and Methodology (2011) ATC/DDD Index 2011.
    1. Zhao L, Cai T, Tian L, Uno H, Solomon SD, Wei LJ (2010) Stratifying subjects for treatment selection with censored event time data from a comparative study. Harvard University Biostatistics Working Paper Series 2010:Working Paper 122

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren